These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24184119)

  • 1. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria.
    Russo GI; Cimino S; Castelli T; Favilla V; Urzì D; Veroux M; Madonia M; Morgia G
    Urol Oncol; 2014 Apr; 32(3):291-6. PubMed ID: 24184119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.
    Russo GI; Castelli T; Favilla V; Reale G; Urzì D; Privitera S; Fragalà E; Cimino S; Morgia G
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):338-42. PubMed ID: 26032650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
    El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
    BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
    Gandaglia G; Ploussard G; Isbarn H; Suardi N; De Visschere PJ; Futterer JJ; Ghadjar P; Massard C; Ost P; Sooriakumaran P; Surcel CI; van der Bergh RC; Montorsi F; Ficarra V; Giannarini G; Briganti A;
    Urol Oncol; 2015 Apr; 33(4):164.e1-9. PubMed ID: 25620154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
    Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C
    BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
    Reese AC; Landis P; Han M; Epstein JI; Carter HB
    J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocols.
    Müller G; Bonkat G; Rieken M; Wyler SF; Bubendorf L; Püschel H; Gasser TC; Bachmann A; Rentsch CA
    Urology; 2013 Apr; 81(4):837-42. PubMed ID: 23395126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
    Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
    Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The number of cores at first biopsy may suggest the need for a confirmatory biopsy in patients eligible for active surveillance-implication for clinical decision making in the real-life setting.
    Villa L; Salonia A; Capitanio U; Scattoni V; Abdollah F; Suardi N; Dell'Oglio P; Freschi M; Montorsi F; Briganti A
    Urology; 2014 Sep; 84(3):634-41. PubMed ID: 25059594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.
    Busch J; Magheli A; Leva N; Ferrari M; Kramer J; Klopf C; Kempkensteffen C; Miller K; Brooks JD; Gonzalgo ML
    BJU Int; 2014 Oct; 114(4):517-21. PubMed ID: 24112652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.